Literature DB >> 3466790

Induction of anti-HIV neutralizing antibodies by synthetic peptides.

T C Chanh, G R Dreesman, P Kanda, G P Linette, J T Sparrow, D D Ho, R C Kennedy.   

Abstract

Two synthetic peptides containing amino acid sequences analogous to the envelope glycoprotein of human T-lymphotropic virus (HTLV) type III (HTLV-III) and lymphadenopathy associated virus (LAV) were produced and used to immunize rabbits. The subsequent rabbit antisera neutralized HTLV-III infectivity in vitro. The two synthetic peptides corresponded to regions associated with the gp120 or gp41 subunits respectively, of human immunodeficiency virus (HIV). This data indicates that at least two neutralizing epitopes are present on the envelope glycoprotein of HIV and these epitopes are associated with two distinct virus envelope glycoproteins. Antisera generated against these peptides neutralized infectivity of two different isolates of HTLV-III. The data is discussed in terms of possible strategy for developing an effective vaccine against the etiologic agents of acquired immune deficiency syndrome (AIDS).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3466790      PMCID: PMC1167262          DOI: 10.1002/j.1460-2075.1986.tb04607.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  47 in total

1.  PROPERTIES OF DIFFERENT ARTIFICIAL ANTIGENS IMMUNOLOGICALLY RELATED TO TOBACCO MOSAIC VIRUS.

Authors:  F A ANDERER; H D SCHLUMBERGER
Journal:  Biochim Biophys Acta       Date:  1965-03-08

2.  An improved polystyrene support for solid phase peptide synthesis.

Authors:  J T Sparrow
Journal:  J Org Chem       Date:  1976-04-16       Impact factor: 4.354

3.  The specificity of antibodies to a peptide determinant of the tobacco mosaic virus protein induced by immunization with the peptide conjugate.

Authors:  F J Fearney; C Y Leung; J D Young; E Benjamini
Journal:  Biochim Biophys Acta       Date:  1971-09-28

4.  Prediction of protein antigenic determinants from amino acid sequences.

Authors:  T P Hopp; K R Woods
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

5.  Antibodies that react with predetermined sites on proteins.

Authors:  J G Sutcliffe; T M Shinnick; N Green; R A Lerner
Journal:  Science       Date:  1983-02-11       Impact factor: 47.728

6.  Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence.

Authors:  J L Bittle; R A Houghten; H Alexander; T M Shinnick; J G Sutcliffe; R A Lerner; D J Rowlands; F Brown
Journal:  Nature       Date:  1982-07-01       Impact factor: 49.962

7.  Cross-reactions of antisera against the terminal amino acid and dipeptide of tobacco mosaic virus.

Authors:  F A Anderer; H D Schlumberger
Journal:  Biochim Biophys Acta       Date:  1966-01-25

8.  An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction.

Authors:  H Masur; M A Michelis; J B Greene; I Onorato; R A Stouwe; R S Holzman; G Wormser; L Brettman; M Lange; H W Murray; S Cunningham-Rundles
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

9.  Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency.

Authors:  M S Gottlieb; R Schroff; H M Schanker; J D Weisman; P T Fan; R A Wolf; A Saxon
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

10.  Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions.

Authors:  F P Siegal; C Lopez; G S Hammer; A E Brown; S J Kornfeld; J Gold; J Hassett; S Z Hirschman; C Cunningham-Rundles; B R Adelsberg
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

View more
  74 in total

1.  Evidence against extracellular exposure of a highly immunogenic region in the C-terminal domain of the simian immunodeficiency virus gp41 transmembrane protein.

Authors:  Thomas S Postler; José M Martinez-Navio; Eloísa Yuste; Ronald C Desrosiers
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

Review 2.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

3.  Examination of sera from human immunodeficiency virus type 1 (HIV-1)-infected individuals for antibodies reactive with peptides corresponding to the principal neutralizing determinant of HIV-1 gp120 and for in vitro neutralizing activity.

Authors:  R Q Warren; S A Anderson; W M Nkya; J F Shao; C W Hendrix; G P Melcher; R R Redfield; R C Kennedy
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

4.  Generation of hybrid genes and proteins by vaccinia virus-mediated recombination: application to human immunodeficiency virus type 1 env.

Authors:  L Gritz; A Destree; N Cormier; E Day; V Stallard; T Caiazzo; G Mazzara; D Panicali
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

5.  Two immunodominant domains of gp41 bind antibodies which enhance human immunodeficiency virus type 1 infection in vitro.

Authors:  W E Robinson; M K Gorny; J Y Xu; W M Mitchell; S Zolla-Pazner
Journal:  J Virol       Date:  1991-08       Impact factor: 5.103

6.  Differential functional phenotypes of two primary HIV-1 strains resulting from homologous point mutations in the LLP domains of the envelope gp41 intracytoplasmic domain.

Authors:  Jason T Newman; Timothy J Sturgeon; Phalguni Gupta; Ronald C Montelaro
Journal:  Virology       Date:  2007-06-19       Impact factor: 3.616

7.  B- and T-lymphocyte responses to an immunodominant epitope of human immunodeficiency virus.

Authors:  R D Schrier; J W Gnann; A J Langlois; K Shriver; J A Nelson; M B Oldstone
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

8.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

9.  Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

Authors:  L E Brown; D O White; C Agius; B E Kemp; N Yatzakis; P Poumbourios; D A McPhee; D C Jackson
Journal:  Arch Virol       Date:  1995       Impact factor: 2.574

10.  The site of an immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 does not constitute the neutralization epitope.

Authors:  C Wilson; M S Reitz; K Aldrich; P J Klasse; J Blomberg; R C Gallo; M Robert-Guroff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.